ClinicaliQ Trial Snapshot
- Exercise Prescription in Children With Hypertrophic Cardiomyopathy — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07595354.
- What is being tested: The safety and efficacy of structured exercise prescription in children with hypertrophic cardiomyopathy (HCM), challenging the traditional conservative approach that has historically restricted physical activity in this population.
- Patient eligibility overview: Children diagnosed with HCM, including those with genetic predisposition and varying disease severity, are eligible to participate in this exercise intervention trial.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Hypertrophic Cardiomyopathy (HCM) is an inherited cardiac condition that affects the heart muscle of adults and children. Historically, doctors have been cautious about encouraging patients with HCM to exercise, as they were worried it could be unsafe due to the risk of heart problems or emergencies. But recent evidence shows that the risks of exercise for a patient with HCM are far lower than previously thought and exercise has many benefits for a child's general health and mental well-being and is an important part of their social development. One way…
Eligibility Snapshot
- : * Undergoing screening for HCM due to a family history or gene-positive * Aged 10 to 18 years (inclusive) * Known to the inherited cardiac conditions clinic at Alder Hey Children's Hospital * Normal cardiac function * Able to complete an exercise log weekly with support from carers * Child or carer able to participate in telephone follow-up
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.